Clinical Trial Update: Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating bevacizumab with or without thalidomide in relapsed or refractory multiple myeloma; the study status is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Bevacizumab (bevacizumab)
• Thalidomide (thalidomide)

Snippet

Sponsor: California Cancer Consortium | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED